secwatch / observer
8-K filed August 22, 2023, 7:59 PM ET ticker ONCO CIK 0001782107
leadership confidence high sentiment negative materiality 0.70

Blue Water Biotech CEO resigns; interim CEO appointed; Audit Committee reviews employee expenditures

Onconetix, Inc.

item 5.02item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joseph Hernandez

Chairman, Chief Executive Officer, and Member of the Board of Directors
ONCO · Onconetix, Inc.
Effective
2023-08-16
Successor
James Sapirstein
Filed
August 22, 2023, 7:59 PM ET
Joseph Hernandez resigned as Chairman, Chief Executive Officer, and a member of the Board of Directors (the “Board”) of Blue Water Biotech, Inc. (the “Company”).
Appointed (interim)

James Sapirstein

Interim Executive Chairman
ONCO · Onconetix, Inc.
Effective
2023-09-30
Filed
August 22, 2023, 7:59 PM ET
the Board appointed James Sapirstein to serve as Interim Executive Chairman, which appointment shall be effective September 30, 2023.
Role change (interim)

Jon Garfield

Chief Financial Officer and interim principal executive officer
ONCO · Onconetix, Inc.
Effective
2023-08-16
Filed
August 22, 2023, 7:59 PM ET
Effective August 16, 2023, Board has appointed Jon Garfield, the Company’s Chief Financial Officer, to serve as the Company’s interim principal executive officer during the pendency of Mr. Sapirstein’s appointment.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Hernandez resigned as Chairman, Chief Executive Officer, and Member of the Board of Directors at Onconetix, Inc..

Action
resigned
Role
Chairman, Chief Executive Officer, and Member of the Board of Directors
Exact text from the filing
Joseph Hernandez resigned as Chairman, Chief Executive Officer, and a member of the Board of Directors (the “Board”) of Blue Water Biotech, Inc. (the “Company”).
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

James Sapirstein was appointed as Interim Executive Chairman at Onconetix, Inc..

Action
appointed
Role
Interim Executive Chairman
Exact text from the filing
the Board appointed James Sapirstein to serve as Interim Executive Chairman, which appointment shall be effective September 30, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jon Garfield was appointed as Chief Financial Officer and interim principal executive officer at Onconetix, Inc..

Action
appointed
Role
Chief Financial Officer and interim principal executive officer
Exact text from the filing
Effective August 16, 2023, Board has appointed Jon Garfield, the Company’s Chief Financial Officer, to serve as the Company’s interim principal executive officer during the pendency of Mr. Sapirstein’s appointment.
View on SEC.gov

Onconetix, Inc. filing history →

Source: SEC EDGAR
accession 0001213900-23-069983
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.